The ASCO 2024 Annual Meeting showcased several exciting developments in breast cancer research, as discussed by Dr. Alexandra Thomas and Dr. Virginia Kaklamani.
One key area of interest was the data from the postMONARCH study, which examined the use of a CDK4/6 inhibitor after progression on a previous CDK4/6 inhibitor. The researchers were eager to see if this sequential approach would provide a clinical benefit.
Another highly anticipated presentation focused on using anti-Müllerian hormone (AMH) levels to identify premenopausal patients who may benefit more from chemotherapy in the RxPONDER trial. This simple test could help guide treatment decisions for these patients, who often struggle with the decision to undergo chemotherapy.
The meeting also featured abstracts exploring the use of circulating tumor DNA (ctDNA) detection in the adjuvant setting, as well as the potential of artificial intelligence (AI) to analyze tumor histology for prognostic and predictive information. These advancements could lead to more accessible and cost-effective tools for breast cancer management.
Additionally, the DESTINY-Breast06 trial, which evaluated the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in patients with HER2-low or HER2-ultralow breast cancer, generated significant interest. The researchers were eager to see if the data would support expanding the use of T-DXd beyond the traditional HER2-positive population.
Other notable presentations included the A-BRAVE trial, which explored the role of avelumab in the adjuvant setting, and the PATRICIA cohort from the SOLT-1303 study, which investigated a non-chemotherapy regimen of palbociclib, trastuzumab, and endocrine therapy for patients with HER2-positive, luminal-type metastatic breast cancer.
Finally, the researchers discussed the potential implications of the findings from a study examining the benefit of endocrine therapy in patients with low (1%-10%) estrogen receptor positivity, which could help guide treatment decisions for this patient population.
To Another Language
from source content
www.medscape.com
Key Insights Distilled From
by Virginia Kak... at www.medscape.com 06-06-2024
https://www.medscape.com/viewarticle/asco-2024-whats-new-breast-cancer-research-2024a1000al7Deeper Inquiries